Parabilis advances desmoid-tumor program after updated response data
Parabilis Medicines ($PBLS) reported a 72.2% response rate for investigational zolucatetide in a 32-week analysis of desmoid-tumor patients who started at doses of at least 450 milligrams. That figure represents 13 responses among 18 evaluable patients at the landmark. Across the broader group of 46 response-evaluable patients receiving those starting doses, disease control was 100%, with no disease progression reported. The company also disclosed FDA alignment on dosing, a placebo-controlled de
0